Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis

Paclitaxel remains the first-line chemotherapy regimen for many malignant tumors. However, prognosis and adverse events under different dosing regimens (one-week versus three-week treatment) remain contradictory in many randomized controlled trials (RCTs). Here, we performed a comprehensive meta-ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Shitong, Peng, Ting, Meng, Yifan, Cao, Canhui, Gao, Peipei, Wu, Ping, Zhi, Wenhua, Wei, Ye, Chu, Tian, Liu, Binghan, Wei, Juncheng, Huang, Xiaoyuan, Ding, Wencheng, Cheng, Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908930/
https://www.ncbi.nlm.nih.gov/pubmed/35218640
http://dx.doi.org/10.18632/aging.203919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908930/
https://www.ncbi.nlm.nih.gov/pubmed/35218640
http://dx.doi.org/10.18632/aging.203919

Ejemplares similares